The long-anticipated reinforcement of state-owned insurance capital has officially materialized. On September 6, five major central-level insurance institutions, including China Life Insurance (Group), China Taiping Insurance (Group), China Export & Credit Insurance Corporation, People's Insurance Company of China (Group), and China Reinsurance (Group), collectively disclosed capital replenishment plans, securing a combined 70 billion yuan injection from the Ministry of Finance. This marks the first time the insurance industry has received a systematic, centralized capital injection from the state, with the pace of policy implementation significantly exceeding market expectations.

Although regulators had signaled in 2025 the need for capital replenishment among large insurers, the 2026 government work report focused exclusively on bolstering the capital of large state-owned banks, allocating 300 billion yuan in special treasury bonds to support the banking system without mentioning the insurance sector. This synchronized capital injection across multiple insurers now overturns the market's previously delayed expectations, officially positioning the insurance industry as a core component in the financial system's capital strengthening efforts.

The injection adopts a differentiated approach: for three non-listed groups, capital is injected directly into the parent company, while for the two listed insurers, the Ministry of Finance will subscribe to targeted share placements in full. Industry observers widely view this round of large-scale capital replenishment as precautionary capital reinforcement rather than a risk rescue operation. Currently, the solvency ratios of major insurers remain well above regulatory safety thresholds. The primary purpose is to offset capital consumption pressures arising from the implementation of the second phase of the "C-ROSS" regulatory framework and the downward trend of the 750-day moving average government bond yield curve, which serves as the core benchmark for assessing insurance liabilities.

External experts highlight the significance of this move extends well beyond just the involved firms. In the short term, it immediately enhances the stability of these insurers and their policy claim safety buffers. In the medium term, leveraging "national credit plus fiscal capital" will enable insurance funds to better serve as long-term capital supporting technological innovation, inclusive finance, and capital market development. In the long run, it aims to strengthen state-owned insurance leaders, enhance their role as economic shock absorbers and social stabilizers, and reserve capacity for participating in industry risk resolution and consolidation, promoting high-quality development through improved capital adequacy and governance.

Differentiated Capital Replenishment Models

The 70 billion yuan injection does not adopt a one-size-fits-all approach; instead, it is tailored based on institutional attributes and listing status. For the three non-listed entities, China Life Insurance (Group), China Taiping Insurance (Group), and China Export & Credit Insurance Corporation, the Ministry of Finance is injecting capital directly into the parent group. This method bypasses secondary market procedures, allowing for the most rapid augmentation of core capital to fortify risk resilience.

As the industry leader, China Life Insurance (Group) receives the largest single injection of 35 billion yuan. The company stated this capital replenishment will further enhance its operational stability and risk resilience, injecting strong momentum into focusing on its core business, improving governance, and pursuing differentiated development.

China Export & Credit Insurance Corporation, which undertakes policy-oriented functions, receives 10 billion yuan, which the company says will help ensure medium to long-term financial sustainability, enhance the resilience of operating cash flows, and support its ability to better fulfill policy functions and serve the real economy.

China Taiping Insurance (Group) receives 7 billion yuan. The company notes this increase will further strengthen its risk resistance capabilities, promote balanced and stable key indicators such as solvency, and enhance its capacity to serve national strategies and support high-quality development of the real economy.

For the two listed insurers, People's Insurance Company of China (Group) and China Reinsurance (Group), the approach utilizes market-based private placements fully subscribed in cash by the Ministry of Finance. Of this, People's Insurance Company of China (Group) will use all 15 billion yuan in net proceeds to replenish capital, further solidifying its capital base and enhancing operational stability and risk resistance. China Reinsurance (Group)'s 3 billion yuan private placement of domestic shares is intended to better enable it to function as an economic shock absorber and social stabilizer in the insurance and reinsurance sectors.

Academics point out that direct injection involves the Ministry of Finance increasing capital in the group parent based on state-asset valuations, a relatively simple process that replenishes core capital at the group level. In contrast, the private placement for listed insurers involves issuing shares to the Ministry of Finance at market prices, requiring formal issuance procedures and only replenishing capital at the joint-stock company level, potentially causing short-term earnings dilution.

Compared with banks relying on special treasury bonds for capital replenishment, the two financial sectors' paths to strengthening their capital bases differ fundamentally due to institutional attributes and procedural efficiency. The banking system's path is relatively uniform given that all are listed entities with mature capital replenishment mechanisms. The insurance industry, however, adopts a hybrid approach—"tailoring policies to individual enterprises"—using direct injections for non-listed groups and private placements for listed platforms, thereby balancing procedural efficiency with respect for market-based pricing principles.

Reinforcing Precautionary Capital

Industry consensus holds that this 70 billion yuan injection is not a risk rescue for the insurance sector but rather a classic proactive, precautionary capital reinforcement measure. Currently, the solvency positions of leading state-owned insurers are all within regulatory safe zones. This concentrated injection primarily aims to address the long-standing capital pressure challenges faced after the full implementation of the second phase of C-ROSS, proactively thickening risk safety cushions to loosen constraints for future business expansion and asset allocation optimization.

The second phase of C-ROSS, officially known as the "Insurance Company Solvency Regulatory Rules (II)," took effect in the first quarter of 2022. Its full implementation significantly tightened capital measurement standards across the industry, notably increasing the risk capital charges for equity and long-term equity investments. Compounded by the drag of prolonged low interest rates on fixed-income returns and the persistent decline in the 750-day moving average government bond yield curve, the industry's overall actual capital has faced sustained pressure. This injection is a forward-looking move to address these long-term developmental pressures.

Recent analysis from brokerages echo this view: the first inclusion of insurance institutions in the national capital injection framework underscores the demonstrative role of precautionary capital supplementation. Unlike previous injections which only targeted banks, this round includes insurers for the first time, reflecting policy guidance to concentrate capital in premium, top-tier insurance companies. Given that the solvency of major insurers is currently adequate, it is anticipated that this injection is a long-term capital arrangement and policy function implementation at the group level, not a risk rescue for listed entities.

Insiders characterize this as a forward-looking, precautionary capital injection from the shareholder level. The objective is to hedge against low interest rate erosion and mitigate the core capital consumption impacts from the downward trend in the 750-day government bond yield curve in recent years. The injection directly augments capital base, stabilizing solvency adequacy ratios.

The core logic behind this injection is rooted in "proactive prevention" rather than "passive remedy." After the full implementation of C-ROSS Phase II, capital recognition has become stricter and minimum capital requirements higher. Simultaneously, the continuing decline of the 750-day yield curve erodes core capital, and under prolonged low interest rates, life insurers face particularly acute asset-liability matching pressures. Waiting for endogenous capital generation through profitability is not practically feasible. Under the strain of spread losses, industry earnings are insufficient to simultaneously support business expansion and capital accumulation. This injection is about proactively thickening the "safety cushion" before risks become explicit, allowing top insurers to maintain strategic initiative during the rate downturn rather than reacting passively.

Expanding Room for Long-Term Insurance Capital in the Market

From a medium to long-term perspective, another significant value of this capital replenishment lies in relaxing the capital constraints on insurers' equity investments. Industry analysis suggests that as one of the largest long-term institutional investor pools in the A-share market, insurance funds possess core advantages of long duration, stable risk appetite, and a focus on long-term returns. They are essential capital for stabilizing the capital market and cultivating new quality productive forces.

However, due to C-ROSS Phase II rules, each increase in equity or stock allocation previously consumed substantial core capital, suppressing institutions' willingness and capacity to increase positions. With this fiscal injection now complete, the core capital adequacy of the five insurers has improved, and their solvency safety margins have significantly widened. The previously constrained equity allocation space is now unlocked, helping leverage the market stabilization function of "patient capital."

It's important to clarify that this 70 billion yuan is not direct incremental capital for market entry. Rather, it works indirectly by enhancing capital strength and releasing regulatory headroom, activating insurers' existing premium funds and new allocation capacities to channel continuous long-term capital into the A-share market and the real economy.

Analysts note this injection will, in the short term, alleviate pressure on solvency—particularly core solvency adequacy—from the declining "750 curve." In the medium term, it resolves concerns for insurers increasing their long-term equity market investments. Over the long run, it enhances the capital strength and influence of state-owned commercial insurance central enterprises within the industry.

With solvency supplemented, insurers can further cast off the capital shackles restricting increased equity allocations, enabling a better response to calls for long-term capital market participation. In practice, however, insurers are unlikely to dramatically increase positions immediately. While the capital constraint on equity allocation is indeed relaxed, the pace of increasing positions will depend on market valuations, interest rate trends, and each institution's asset allocation strategy.

From a sector preference standpoint, insurers are currently continuously increasing allocations to high-dividend assets, marginally adding to sectors such as power and utilities, steel, and coal. Simultaneously, they are exploring investment opportunities with long-term growth potential in areas like AI, semiconductors, new energy, and biomedicine. The dual-track strategy remains mainstream: using high-dividend, large-cap blue-chip stocks as a core position while flexibly participating in structural opportunities within tech-growth sectors. The path of market entry is also undergoing profound changes, shifting from "secondary market stake building" towards "IPO strategic placements and cornerstone investments," with insurers' roles evolving from "financial investors" to "strategic investors."